Horizon hits the gas pedal on renewed early-stage R&D, enlisting a Mitch Gold biotech in a $1.5B+ deal

Horizon Therapeutics is no stranger to swinging deals, and on Thursday the Irish biotech grabbed itself a new partner to help build out its early-stage pipeline.

In a collaboration expected to bring up to four new programs into the fold, Horizon is teaming up with Alpine Immune Sciences in a...

Click to view original post